Abstract: A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more ribofuranose derivatives having the Formula (I): wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such as antivirals or agents effective against inflammatory bowel disease.

Abstract: A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more ribofuranose derivatives having the Formula (I): wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such as antivirals or agents effective against inflammatory bowel disease.

Abstract: A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more ribofuranose derivatives having the Formula (I): wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such as antivirals or agents effective against inflammatory bowel disease.

Abstract: A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more antivirals selected from the group consisting of an antiviral active against herpes viruses, pharmaceutically acceptable salts thereof, and mixtures thereof, excluding anti-inflammatory agents selected from the group consisting of salicylates and salicylates prodrugs. The antiviral may be used in combination with additional active agents effective against inflammatory bowel disease.

Abstract: A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more ribofuranose derivatives having the Formula (I): wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such as antivirals or agents effective against inflammatory bowel disease.

Abstract: A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more ribofuranose derivatives having the Formula (I): wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such as antivirals or agents effective against inflammatory bowel disease.

Abstract: A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more ribofuranose derivatives having the Formula (I): wherein R is a group selected from a carboxamide, an amidine, and pharmaceutically acceptable acid addition salts thereof, and the configuration at the C2 carbon of the ribofuranose moiety is D or L. The one or more ribofuranose derivatives (I) may be used in combination with further active agents such as antivirals or agents effective against inflammatory bowel disease.

Abstract: The use of 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine and pharmacological acid addition salts thereof for the release of growth hormone.

Abstract: The use of 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine and the pharmacological acid addition salts thereof for the release of growth hormone.

Abstract: This invention relates to the transdermal administration of compounds of general formula I ##STR1## wherein R.sub.1, R.sub.2 and X have the meanings given in the text, and to a therapeutic system for the transdermal administration of this compound.

Abstract: Disclosed is a method of lowering the prolactin level in the blood or serum of a person which method comprises administering a therapeutically effective amount of 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo-[5,4-d]azepine or a non-toxic, pharmaceutically acceptable acid addition salt thereof.

Abstract: Pharmacologically active peptides with opiate-like activity are provided having stability to proteases. The products can be obtained by enzymatic digestion of casein.The active peptides have the grouping Tyr-Pro-A where Tyr is tyrosine, Pro is proline and A is any amino acid group.

Abstract: Pharmacologically active peptides of the following formulas are described:L--Tyr--X--L--Phe--X--TL--Tyr--X--L--Phe--X--A--TL--Tyr--X--L--Phe--X--A--X--TL--Tyr--X--L--Phe--X--A--X--B--Tin which L--Tyr is the N-terminal amino acid residue L-tyrosine, X any amino acid residue of the D-form, L--Phe is the amino acid L-phenylalanine, A and B are any desired amino acid residues and T is the C-terminal carboxyl group, which is further disclosed in the description.The substances are suitable for the therapy of diseases.

Abstract: Peptides of the formula Tyr.sup.1 -X-A-Pro-B-Pro-C-Pro-D, in which Tyr.sup.1 is equal to the amino acid tyrosine and Pro is equal to the amino acid proline; A, B, C, D is any desired amino acid in the L-form and X any amino acid in the D-form, except D-proline, D-alanine, D-threonine and D-valine, preferably D-serine, D-arginine or D-methionine; they act opiate-like and may be used as medicaments and animal medicaments.

Abstract: Peptides of the formula Tyr.sup.1 -X-A-Pro-B-Pro-C . . . . . . . . , in which Tyr.sup.1 is equal to the amino acid tyrosine and Pro is equal to the amino acid proline; A, B, C is any desired amino acid in the L-form and X any amino acid in the D-form; they act opiate-like and may be used as medicaments and animal medicaments.

Abstract: A tobacco-filled smoking article adapted to produce a low proportion of toxic substances such as carbon monoxide in the gaseous products of combustion comprising a tobacco filling and means to confine said tobacco, wherein within the volume of tobacco, there is at least one tobaccoless region separated from the tobacco by a substantially air-impermeable partition.

Abstract: A manually actuated device for modifying conventional tobacco articles to provide articles with a low content of noxious substances, comprising a holder for holding the tobacco articles and a device for creating a tobacco-free space at a position adjacent to the longitudinal axis of the tobacco article.